The proteasome, that large subcellular grinder that recycles protein, plays a major role in localized degeneration of axons, according to a report in this week's Neuron. Such neuronal damage typically follows traumatic injury, but it can also be caused by a variety of neurodegenerative diseases, including Alzheimer's.

Principal author Zhigang He and colleagues at the Children's Hospital and Harvard Medical School, Boston, and Stanford University, California, examined the role of the proteasome in Wallerian degeneration, the delayed though rapid deterioration of axons on the distal side of a lesion.

Joint first authors Qiwei Zhai and Jing Wang asked what effect inhibitors of the proteasome machinery may have on the Wallerian process. They found that both reversible (the peptide MG132) and irreversible (lactacystin) proteasome inhibitors, while having no effect on normal cultured neurons, significantly delayed degeneration of axons after they were severed. In the absence of the inhibitors, fragmentation of the axon skeleton was clearly visible within eight hours, but in their presence, this process was delayed by at least another eight hours. Furthermore, the authors found that MG132 could slow down depolymerization of tubulins, suggesting that the proteasome is involved in the degeneration of microtubules.

The proteasome, being the final destination for proteins tagged for proteolytic degradation, is intimately associated with the ubiquitination pathway, one which flags proteins with strings of the small peptide ubiquitin. To test the relationship between Wallerian degeneration and the ubiquitin proteasome system, Zhai and Wang engineered neurons to express a yeast ubiquitin protease that can effectively reverse protein ubiquitination. The authors found that in these cells, about 40 percent of axons had degenerated eight hours after being severed, whereas in control cells, that percentage was typically about 90.

The results tie in with earlier observations that axons of Wlds mice, which exhibit slow Wallerian degeneration, are somehow protected by a mutation that leads to expression of a chimeric protein containing a ubiquitin conjugation factor (see ARF related news story). In the present study, however, Zhai, Wang, and colleagues extend the observations beyond Wallerian degeneration by showing that MG132 also prevents degeneration in whole axons deprived of nerve growth factor, implying that the proteasome may be involved in other types of neurodegeneration.—Tom Fagan


Make a Comment

To make a comment you must login or register.

Comments on this content

  1. This interesting manuscript attempts to delineate a relationship between the ubiquitin system and the axonal degeneration of cultured neurons. Strongly presented data suggests that inhibition of proteases results in the marked slowing of this degeneration.

    This reviewer shows concern for the assertion that the proteasome has been adequately assayed, however. While a rational candidate for being the responsible party to degrade neuronal components(and the answer is probably right, anyway) the methods used to assert this cannot produce that conclusion. At the heart of this is the specificity of the inhibitors used and their relationship to the proteasome.

    Figure 1 title is boldly stated. Of the inhibitors used, MG132 is the most directed to the proteasome active site, but even it is not highly specific. The support of a calcium chelator and a tripeptide must be discounted almost summarily. Why was the Lactacystin result not shown in Figure 1? Lactacystin is more specific to the proteasome than the other three. A better title is something that asserts protease inhibitors slow axonal degradation. There are perhaps a hundred targets of these inhibitors, and the proteasome may be the least effected.

    Attempts to support this prior result with a UBP2 transfection is also suspect. UBP2 overexpression alone cannot reverse all Ubiquitylation in a cell. There are 17 UBPs in yeast, and many more in human, with such irritatingly narrow specificity that mapping out anything useful about their targets has proved problematic. The hydrolytic specificity of UBP2 is almost completely unknown, and the understanding of the specificity of hydrolysis of ubiquitylated proteins (not peptides) is nearly absent in the literature. Why would a single overexpression of a single, large UBP with unknown target have any definable relationship to this process? The only mentioned ubiquitin protease with specificity to the neuron is UCHL-1/PGP9.5, which when knocked out produces the GAD mouse. Perhaps this could have been used, or another neuron specific UBP? Or a Velcade like boronate? Or a longer, more specific peptide inhibitor?

    The involvement of calcium dependent proteases is very interesting. If the pathway through calcium proteases to the proteasome (and the relevant substrates) were worked out, perhaps dissecting the targeting E3s and the upregulated proteases would be of use. The work could be followed by "proteomic" attempts at characterizing the upregulated elements of the Ub system, to determine which components are actually being used by the cell to tear down the axon.

    In whole, while the involvement of the proteasome is likely, and the elements of the teardown process have not been illustrated, the effect of this paper on the ubiquitin field is positive, and deserves note as a heads-up start for some biochemical dissection of the pathways involved.


News Citations

  1. Protein Chimera Found to Protect Axons from Degeneration

Further Reading

No Available Further Reading

Primary Papers

  1. . Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. Neuron. 2003 Jul 17;39(2):217-25. PubMed.